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Abstract
Background: Hepatitis B Virus (HBV) co-infection is prevalent among HIV infected individuals because of shared routes and
mechanisms of transmission. The multidimensional immunosuppression from HIV infection causes impaired spontaneous recovery from
an acute HBV infection, predisposing to chronic infection which is worsened by younger age at infection. Co-infection increases the risk
of HBV replication, hepatotoxicity and liver related deaths from Highly Active Antiretroviral Therapy (HAART). The study was
undertaken to highlight the burden of co-infection among HIV positive children in Enugu, determine the associated risk factors and
compare the effect of co-infection between co-infected and non-co-infected children using liver enzyme and CD4 counts.
Materials and Methods: A cross sectional study was carried out among HIV positive children attending the Paediatric ARV clinic of the
University of Nigeria Teaching Hospital, Ituku-Ozalla. A total of 140 HIV infected children aged 18 months to 15 years were recruited.
An interviewer questionnaire was administered. Hepatitis B surface antigen (HBsAg) was determined using Determine test Kit. Baseline
and recent CD4 counts/CD4% were retrieved from the patients’ folders.
Results: Fourteen (10%) were positive for HBsAg. The highest prevalence of HBsAg was observed among children aged 11- 15 years.
The higher the socioeconomic class the less likely the HBsAg positivity. Seven (50%) of the co-infected children had elevated baseline
ALT compared with 57 (45.2%) of non-co-infected children though the difference was not statistically significant (t = 0.6, P = 0.56).
After the initiation of HAART, 10 (76.9%) of the co-infected and 18 (15.1%) of the non-co-infected children had elevated ALT. The
baseline median CD4 count among children ≥ 6 years was 230 cells/mm3 and 360 cells/mm3 respectively among the co-infected and non-
co-infected, (P  = 0.67). However, in children ≤ 5 years, it was 25% and 15 % respectively (P = 0.06).
Conclusion: HBV co-infection among HIV infected children is common in our environment, and co-infection is associated with
impaired immunity and probably liver enzyme derangement.
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Introduction
Human Immunodeficiency Virus (HIV) is an RNA virus that mainly targets the T-lymphocytes bearing CD4. Human
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is a major cause of infant and childhood morbidity,
hospitalization and mortality, has devastated families and complicated the efforts to fight poverty, improve health and promotion of
development (ANECCA, 2005). In 2010, about 33.3 million people, worldwide, were living with HIV including 2.5 million children with
an annual death rate of 1.8 million due to AIDS. Nigeria accounted for about 3.5-4 million people living with HIV including 360,000
children, with 340,000 new infections out of which 170,000 were children. There were also 220,000 AIDS-related deaths
(WHO/UNAIDS, 2010).
Hepatitis B Virus (HBV), on the other hand, is a hepatotropic virus that replicates predominantly in the hepatocytes,
lymphocytes, spleen, kidney and pancreas with areas of highest prevalence being the sub-Saharan Africa and South-East Asia
(Yazigi,Balistrere, 2007, WHO/Hepatitis B). It is also a major public health problem with increased risk of chronicity in children and
subsequent increase in morbidity and mortality. Younger age at acquisition of infection is the single most important predictor of chronic
carriage (Yazigi, Balistrere, 2007, Uleanya, Obidike, 2015). Worldwide, an estimated two billion people are infected, with 350-400
million of them remaining chronic carriers of HBV, a leading cause of chronic liver diseases and liver-related mortality (WHO/Hepatitis
B, Puoti et al, 2008, Sharma et al, 2008, Rouet et al, 2008, Mphahlele et al, 2002, Kire, 1996). It has also been estimated that 15 - 25% of
the chronic carriers will die of these sequelae (WHO/Hepatitis B). Consequently, worldwide estimated annual mortality directly related to
hepatitis B liver disease and cancer is between 600,000-1 million (Puoti et al, 2008, Sharma et al, 2008, Mphahlele et al, 2002). Nigeria is
hyper-endemic with endemicity rate as high as 37-46% (Emechebe et al, 2009).
Hepatitis B virus co-infection is common among patients with HIV, because of shared routes and mechanisms of transmission
(Thio et al, 2002, Levy et al, 2006). It has been estimated that about 6 to 15% of the 33.3 million people living with HIV infection are
also chronically infected with HBV (Psevdos et al, 2010). The multidimensional immunosuppression caused by HIV can: compromise
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one’s ability to recover spontaneously from an acute HBV infection thus leading to a chronic infection; lower incidence of spontaneous
loss of HB e antigen (HBeAg) or HBsAg and cause more rapid decline in hepatitis B surface antibody over time (Thio et al, 2002,
Psevdos et al, 2010, Mgonda, 2004). Co-infection increases the risk for HBV-related liver disease progression and also the risk for
antiretroviral drug related hepatotoxicity (Thio et al, 2005). This high risk of hepatotoxicity may then imply an increased risk of death
from the liver disease in co-infected people (Thio et al, 2002). In viral hepatitis and drug induced hepatotoxicity, alanine transaminase is
the most specific marker of hepatotoxicity (Baron et al 1994). Paradoxically, there is low serum alanine transferase concentration but
high HBV DNA and HBe Ag levels found in the serum of co-infected persons (Puoti et al, 2008, Kellerman et al 2003, Thio et al, 2002).
Such co-infected persons are at higher risk for a more rapid progression to chronic hepatitis, HBV-related cirrhosis and hepatic de-
compensation than are only HBV infected persons (Puoti et al, 2008, Kellerman et al, 2003). It has also been documented that the rate of
liver-related deaths from progressive liver disease are highest among those with lowest CD4 count, which also increases after the
introduction of HAART. It is noted that CD4 depletion alter the intrahepatic cytokine milieu contributing to increased fibrosis (Thio et al,
2002). Co-infection therefore poses a treatment challenge. With increasing access to HAART, it is expected that AIDS-related mortality
will become reduced (Puoti et al, 2008, Rouet et al, 2008). However, it is most likely that liver disease related to chronic HBV infection
or drug-induced hepatotoxicity will increase and liver failure may emerge as a major cause of death whether amongst the treated or
untreated co-infected patients.
This study was, therefore, undertaken to highlight the burden of co-infection in our environment, determine the associated risk
factors and compare the effect of co-infection as determined by derangement in liver enzyme and CD4 counts of co-infected children with
that of surface antigen negative HIV infected children. Such information will be of help to health policy makers in generating guidelines
for effective management and/or prevention of both infections.
Methods
This was a cross sectional study carried out among HIV positive children attending the paediatric antiretroviral (ARV) clinic of
the University of Nigeria Teaching Hospital (UNTH), a tertiary medical institution in Enugu. The clinic provides care for about 240 HIV
positive children from Enugu and its environs.
A total of 140 Western Blot confirmed HIV positive children aged 18 months to 15 years were studied with HIV positive
HBsAg negative children serving as controls. Exclusion criteria were those aged less than 18 months or older than 15 years, unconfirmed
HIV status and those whose parent(s)/guardian did not consent.
Ethical clearance was given by the University of Nigeria Teaching Hospital Health Research and Ethics committee. Informed
consent (both verbal and written) was obtained from the child and the parent(s) or guardian. They were duly educated on the need for,
and benefits of the study. The specimen to be collected and how it was to be collected was explained to them before collection. A
structured interviewer administered questionnaire was designed for this study. Information sought included bio-data, occupation and
educational status of both parents/guardian for the determination of socioeconomic class, risk factors for HBV infection including
previous history and frequency of blood transfusion, histories and instruments of scarification, tattooing, ear piercing, circumcision, use
of contaminated needles and syringes for injection (either used or reused needle or syringe considered as contaminated), intravenous drug
use, histories of sex (where necessary), and sharing of tooth brush were obtained. In this study, co-infection was defined by the presence
of HBsAg positivity in HIV positive children.
Patient’s baseline and recent CD4 count/CD4% and alanine aminotransferase results were retrieved from their folders. Assays
for HBsAg was done using Abbott DETERMINE HBsAg test kits - an enzyme immunoassay (specificity of 99.85% and a sensitivity of
94.64%). The test was then read after a waiting interval of 15 minutes to 24 hours (as specified by the manufacturer).
The data was analysed using SPSS version 15. Measures of central tendencies – mean and median were used to summarize
quantitative and qualitative variables where applicable. Frequency tables were constructed as appropriate and analytical tests of
significance were done using the Student t- test for continuous variables, Chi square and Fischer’s exact tests for non-continuous
variables and p value at the level of < 0.05 was accepted as significant. Odds ratios for the risk factors were calculated. Socioeconomic
class was determined using the method proposed by Oyedeji (Oyedeji, 1985).
Results
A total of 140 questionnaires were administered with a 100% response rate. Blood samples were collected and analysed from
all 140 subjects for HBsAg. Eight and seven subjects had only baseline ALT and CD4 results respectively. These were confirmed HIV
positives but were new to the clinic.
The age and sex distribution of the study populations is as shown in Table 1. The mean age of subjects was 7.3 ± 3.6 years.
There were 74 males and 66 females with a male to female ratio of 1.1: 1. The majority of the subjects 61 (43.6%) were in the age range
of 6-10 years and the least represented age range was 11-15 years – 29 (20.7%). The socioeconomic class of the subjects is also as shown
in Table 1. Most were in the lower class.
Of the 140 children studied, 14 were positive for HBsAg, giving a prevalence rate of 10%. Ten (9.1%) of the HBsAg positive
subjects were from the lower socioeconomic class, four (18.2%) from the middle class while none among the upper class was positive for
HBsAg. Ten (13.5%) out of the 74 HIV positive males and 4 (6.1%) of the 66 HIV positive females were also positive for HBsAg. The
prevalence of HBsAg increased with age among the subjects (Table 2). However, the highest prevalence was found among four children
(13.8%) aged 11-15 years, (χ2 = 1.5, p = 0.47)
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None of the subjects was involved with intravenous drug injection though all had received intramuscular injections for one reason or the
other as shown in Table 3. However, 19 (13.6%) used contaminated needle/syringes, 42 (30%) had past history of blood transfusion, 76
(54.3%) were circumcised, 33 (23.6%) had scarification marks, 3 (2.1%) had a history of tattoo /ritual marks, 65 (46.4%) had ear
piercing, while 9 (6.4%) shared toothbrushes. One subject (0.7%) was involved in unprotected sex (a victim of sexual assault). The
observed differences between the risk factors and HBsAg positivity were not statistically significant. However, the odds ratio of the risk
of transmission of HBV through these risk factors is as shown in table 3.
Among the 14 co-infected children, 7 (50.0%) had elevated baseline alanine amino-transaminase (ALT) above the upper limit
of normal while 7 (50.0%) had baseline ALT within normal limits. Of the 126 HIV positive but HBsAg negative children, a total of 57
(45.2%) had elevated baseline ALT while most (69 [54.8%]) had baseline ALT within normal limits. Having been initiated on
antiretroviral drugs for varying periods, among the co-infected children, 10 (76.9%) now had elevated ALT while three (23.1%) had
normal ALT. Eighteen (15.1%) of the HBsAg negative HIV positive children had normal ALT while 101 (84.9%) had elevated ALT
above the upper limit of normal. The mean of baseline ALT among the HBV co-infected subjects was 17.9 ± 11.6 iu/l while it was 19.3 ±
17.6 iu/l among the surface antigen negative subjects (126) (t = 0.3, p = 0.76). The mean value of the most recent ALT of the co-infected
children (13) was 24.7 ± 14.2 iu/l while that of the HBsAg negative children (119) was 28.6 ± 23.7 iu/l (t = 0.6, p = 0.56). The
differences were not statistically significant (Table 4).
Table 1: Socio-demographic characteristics of HIV positive Children.
* The lowest age in this study was 18 months
Table 2: Age distribution of HBsAg among HIV positive children
Age range (Years) HIV positive
HBs (+) HBs (-)
N (%) N (%)
1-5 3 (6.0) 47 (94.0)
6 -10 7 (11.5) 54 (88.5)
11-15 4 (13.8) 25 (86.2)
χ2 =1.5, p = 0.47
HIV
Positive
Age Range (years) N (%)
1-5 50 (35.7)
6-10 61 (43.6)
11-15 29 (20.7)
Gender
Male 74 (52.9)
Female 66 (47.1)
Social class
Upper class 8 (5.7)
Middle class 22 (15.7)
Lower class 110 (78.6)
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Table 3: Showing the relative risk of HBsAg positivity among HIV positive children
Risk factors Total Sample HBsAg positive
N (%) χ2 p OR
Blood transfusion
Present 42 7 (16.7) 3.0 0.12 2.6
Absent 98 7 (7.1)
Scarification marks
Present 33 2 (6.1) 0.75 0.52 0.5
Absent 107 12 (11.2)
Tattooing
Present 3 0 (0.0) - - -
Absent 137 14 (10.2)
Circumcision
Present 76 10 (13.2) 1.76 0.26 2.2
Absent 64 4 (6.3)
Intravenous drug use
Absent 140 14 (10.0) - - -
Contaminated
syringe/needle use
Present 19 1 (5.3) 0.55 0.69 0.5
Absent 121 13 (10.7)
Ear piercing
Present 65 4 (6.2) 1.99 0.26 0.4
Absent 75 10 (13.3)
Sharing of toothbrush
Present 9 1 (11.1) 0.01 0.91 1.1
Absent 131 13 (9.9)
Unprotected sex
Present 1 0 (0.0) - - -
Absent 139 14 (10.1)
Table 4: Baseline and Recent ALT of HIV infected children
Mean (SD)
HBsAg
Positive
(N)
status
Negative
(N)
Baseline
(ALT (iu/L) 17.9 (±11.6)
(14)
t = 0.3,
19.3 (±17.6)
(126)
p = 0.76
Recent
ALT (iu/L) 24.7 (± 14.2)
(13)
28.6 (± 23.7)
(119)
t = 0.6, P = 0.56
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Table 5: Median and Mean CD4 count/CD4% of HIV infected children
Baseline
(Mean ±
Median
SD)
Recent
(Mean±
Median
SD)
HBsAg
positive
HBsAg
negative
HBsAg
Positive
HBsAg
negative
CD4 count
(cells/mm3)
Number of children
230.50
(386.7 ± 419.8)
11
360
(458.3 ±352.2)
79
682
(712.2 ± 610.5)
10
723
(741.2± 447.2)
78
t = 0.6 p = 0.54 t = 0.19 p = 0.85
CD4% 25
(28.2 ±13.0)
15
(16.3 ± 10.3)
21.8
(20.8 ± 9.8)
30.2
(29.5 ± 10.7)
Number of children
3
t = 1.9
47
P = 0.06
3
t = 1.4
42
P = 0.18
Table 6: Immunologic classification of HIV positive children ≥ 6 years 
CD4 range Baseline CD4 Recent CD4
(Cells/mm3) HBsAg
positive
N (%)
HBsAg
negative
N (%)
HBsAg
positive
N (%)
HBsAg negative
N (%)
<200 5 (45.5) 22 (27.8) 4 (40.0) 7 (9.0)
201- 349 1 (9.1) 15 (19.0) 0 (0.0) 8 (10.3)
350- 499 2 (18.2) 15 (19.0) 0 (0.0) 10 (12.8)
≥ 500 3 (27.3) 27 (34.2) 6 (60.0) 53 (67.9)
Fischer’s exact
test
P=0.67 Fischer’s exact test
P = 0.027
Table 7: Immunologic classification of HIV positive subjects ≤ 5 years. 
Fischer’s exact test P= 0.079
HBsAg status
Baseline CD4% Positive
N (%)
Negative
N (%)
< 15 0 (0.0) 21 (44.7)
15 – 20 1 (33.3) 15 (31.9)
20-25 1 (33.3) 3 (6.4)
> 25 1 (33.3) 8 (17.0)
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The median of baseline CD4 count of HBsAg negative children ≥ 6 years was 360 cells/mm3, with a mean of 458.3 ± 352.2
cells/mm3 while the co-infected children ≥ 6 years had a median baseline CD4 count of 230 cells/mm3 with a mean of 386.7 ± 419.8
cells/mm3 (t = 0.6, p = 0.60) (Table 5). The median of their most recent CD4 count (all having been on HAART for varying periods), of
the children without HBV co-infection was 723 cells/mm3 with a mean of 741.2 ± 447.2 cells/mm3 while that of the co-infected was 682
cells/mm3 with a mean of 712.2 ± 610.5 cells/mm3 (t = 0.19, p  = 0.85). Among the children ≤ 5 years, the baseline median CD4% of
HBsAg positive children was 25% with a mean of 28.2 ± 13.0 while surface antigen negative children had baseline median CD4% of
15% with a mean of 16.3 ± 10.3. Having received HAART for varying periods, the median CD4% of the co-infected children was 21.8%
while that of surface antigen negative children rose to 30.2%.
From the baseline CD4 count, 30 (33.3%) children ≥ 6 years studied did not have significant immunosuppression. Seventeen 
(18.9%) had mild immunosuppression, 16 (17.8%) had advanced immunosuppression and 27 (30%) had severe immunosuppression. Five
(45.5%) of the co-infected subjects were severely immunosuppressed compared with 27.8% (22) of the non-co- infected subjects.
However, there was no significant association between the levels of immunosuppression and HBsAg positivity (p = 0.64). Among the
HIV positive HBsAg negative children, 34.2%, and 27.3% of the co-infected subjects had baseline CD4 count ≥ 500 cells/mm3
respectively. Having been on HAART for varying periods, their most recent CD4 reveals that 40% of the co-infected children still had
CD4 count < 200 compared with 9% of the HIV positive HBsAg negative children (P = 0.027) (Table 6).
Among children ≤ 5 years, 44.7% (21) of the HIV positive HBsAg negative children had baseline CD4% < 15% while none of
the co-infection children had a CD4% < 15%. However, 33.3% (1) of co-infected children had CD4% > 25% while 17% (8) of those
without HBsAg had CD4% > 25% (Table 7).
Discussion
This study revealed a 10% prevalence rate of HBsAg among 140 HIV infected children, which is lower than the 19% and
12.1% among co-infected children in Maiduguri and Ivory Coast (Rouet et al 2008, Ashir et al, 2009) respectively. This difference may
be due to higher prevalence of HIV and HBV infections in these areas compared to Enugu. It is higher than the seroprevalence of 7.7% in
Benin (Sadoh et al, 2011) and 7.8% in Makurdi (Anigilaje,Olutola, 2013). It is also higher than the 1.2% in Dar-es-Salaam (Telatela et al,
2007). The role of universal HB immunization in Tanzania since 1999 may have accounted for this lower prevalence. Generally, this
prevalence of 10% is higher than the estimated 8% for Africa (Puoti et al, 2008). This probably may be because Nigeria is hyper-endemic
(Emechebe et al, 2009) and the fact that HIV infected children tends to have early exposure to HBV risk factors following repeated
illnesses and hospitalizations. The large number of children co-infected with HBV can easily transmit the infection to other children,
considering the fact that HBV is 100 times more infective than HIV (Mgonda, 2004). This makes the infection a major public health
problem that requires enhanced measures of prevention and care in order to achieve eradication in sub-Saharan Africa.
An increasing prevalence of HBsAg with age was observed among the HIV positive children in this study. Other studies have also noted
a similar trend (Telatela et al, 2007, Emechebe et al, 2008). This pattern would suggest that there is a predominance of horizontal
transmission of HBV infection among HIV infected children in our environment. Though the highest number of HBsAg positivity was
found in those children aged 6 -10 years, the highest prevalence of HBsAg was found among those aged 11-15 years. The high
prevalence of co-infected Nigerian children of this age may reflect their inability to lose HBsAg due to their impaired immunity (Levy et
al, 2006). In this study also, zero prevalence was observed in the age group 18 months to 3 years, which implies that vertical transmission
of HBV has remained low in Nigerian women. It may also be that the mothers were not co-infected with HBV, considering the fact that
Ilboudo in Burkina Faso recorded that three co-infected mothers who were positive for HBeAg, HBsAg and HBV DNA vertically
transmitted the virus to their children (Ilboudo et al, 2010). This finding is similar to that in Dar-es-salaam (Telatela et al, 2007).
The social class of the children in this study was not significantly associated with HBsAg positivity. However, it was observed
that the higher the social class, the lower the number of children positive to HBsAg. This is similar to the findings in Bangui (Komas et
al, 2010), and in Enugu (Emechebe et al, 2008). This could be because people in the upper socioeconomic class are less likely to
patronize medical quacks, or indulge in activities that may promote infection with HBV such as alternative medicine.
Though the risk factors in this study were not statistically significant, those transfused were about three times more likely to
have HBV infection than those not transfused. It is worthy to note that blood transfusion may have contributed to this high prevalence
rate considering the fact that infectious HBV can be present in blood without detectable HBsAg (Alexander,Kowdley, 2006). Al-Fawaz
had earlier adduced that even an HBsAg free blood obtained by the very sensitive 3rd generation screening techniques can not completely
safeguard against HBV (Al-Fawaz,Ramia, 1993). Also, it had been noted that history of blood transfusion was a sufficient risk factor for
chronic hepatitis B infection, a major aetiological factor for primary hepatocellular carcinoma in Africa and Southeast Asia (Ndububa et
al, 2001).
Irrespective of age and sex, serum alanine (ALT) levels greater than the upper limits of normal (15 iu/l) is often considered
abnormal. Though the difference in ALT between the co-infected and non-co-infected children was not statistically significant, it was
higher in the study group when compared with normal values. It probably may imply in-apparent liver disease in these children. The
observed higher values among HBsAg negative subjects could be as a result of the fact that seven of the subjects had moderate to severe
hepatic derangement with values of 50-206 iu/l. It is also possible that the higher value is due to other causes of liver disease in HIV
positive individuals considering that 50% of the co-infected children had elevated baseline ALT compared with 45.2% among HBsAg
negative HIV infected children. This differed from findings in Maiduguri (Ashir et al, 2009), and in Dar-es-Salaam (Telatela et al, 2007).
Having been on HAART for varying periods, the mean ALT increased among both the co-infected and non-co-infected children showing
a worsening liver disease probably due to HAART.
The immune status of the co-infected children as depicted by the baseline median CD4 count was lower than in those with HIV
infection alone. They also had lower median CD4 value even after being on HAART for a variable period. The improvement in immune
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status of this children compared with the co-infected was statistically significant. This implies that HBV co-infection significantly
impairs the immune system of HIV positive children and that immunologic failure is commoner among co-infected subjects. This finding
is consistent with those of Anigilaje, et al , Rouet et al Thio et al and Psevdos et al.
Conclusion
Hepatitis B virus infection is common among HIV infected children and co-infection is associated with impaired immunity
(lower baseline CD4 count), even more significantly after initiation of HAART. Hepatitis B Virus co-infection is also associated with
liver enzyme derangement (liver disease) although the difference was not statistically significant and this is probably exacerbated by
HAART.
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